Improved Lipid Target Level Attainment in Patients with Peripheral Artery Disease

(E-pub Ahead of Print)

Author(s): Jörn F. Dopheide, Luise Adam, Sebastian Wiedmer, Mathias Kaspar, Günther Silbernagel, Iris Baumgartner*, Heinz Drexel*

Journal Name: Current Vascular Pharmacology


Become EABM
Become Reviewer
Call for Editor

Abstract:

Background: Patients with peripheral artery disease (PAD) fall under the category of a very high cardiovascular risk. Although, consequent lipid lowering therapy (LLT) is advised, only sparse data on attained target level in PAD exists.

Objectives: We aimed to analyse contemporary guideline recommendations for LLT in symptomatic PAD patients.

Methods: monocentric, prospective, observational study involving 200 symptomatic PAD patients. Guideline target level attainment and LLT were analysed between 2017 and 2019.

Results: Overall 78.5% of the patients were on statin therapy, mainly of high intensity with atorvastatin in 50% and rosuvastatin in 33% of the cases. Average statin dosage adjusted for simvastatin was 55 mg/d. Low density lipoproteincholesterol (LDL-C) was <1.8 mmol/L in 53% and <1.4 mmol/L in 34% of the cases. Mean LDL-C levels were at 1.85 ± 0.88 mmol/L. We observed no difference in the treatment and the target level attainment of patients with a stable PAD (intermittent claudication) or chronic critical PAD. However, patients with ≥1 vascular region affected (i.e. coronary and/or cerebrovascular) were treated more intensively and had lower LDL-C levels than patients with PAD alone.

Conclusion: It appears that there is more awareness and improvement of previously documented undertreatment of LDL-C levels in symptomatic PAD patients. Although statin treatment is initiated in the majority of patients, our findings call for a continuously intensified LLT in symptomatic PAD patients.

Keywords: Peripheral artery disease, lipid lowering therapy, statins, Low density lipoprotein-cholesterol, target attainment.

Rights & PermissionsPrintExport Cite as

Article Details

Published on: 11 January, 2021
(E-pub Ahead of Print)
DOI: 10.2174/1570161119666210111123621
Price: $95

Article Metrics

PDF: 237